Photo by nci from unsplash
Although oncogenic driver mutations in RAS occur in 20% of cancers, heterogeneity in the biologic outputs of different RAS mutants has hampered efforts to develop effective treatments for RAS-mutated cancers.… Click to show full abstract
Although oncogenic driver mutations in RAS occur in 20% of cancers, heterogeneity in the biologic outputs of different RAS mutants has hampered efforts to develop effective treatments for RAS-mutated cancers. In this issue of Science Signaling, Huynh et al. show that even among KRASQ61 mutants, the specific amino acid that is substituted substantially affects mutant KRAS biologic activity and oncogenicity. Description The distinct biochemistry and biology of KRAS Gln61 mutants are revealed (Huynh et al., in 09 August 2022 issue).
Journal Title: Science Signaling
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!